Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsNani daman

    Nani Daman

    Jump to

    • Wockhardt falls 4%, US FDA says co erased key trial data

      The US FDA has said that it is concerned about Wockhardt's responses to the health regulator's queries and lab records are not in compliance with established standards. It also added that comany did not take appropriate actions to resolve defects while actual samples were used as 'trial' injections.

    • Wockhardt up 11% on UK regulator approval for Kadiya unit

      As a result the net impact on the annualised consolidated revenue is expected to be less than £1 million, out of the total annual consolidated revenue of approximately £18 million, from the said facility, it added.

    • Wockhardt may face £1 mn hit due to Kadaiya unit lapses

      The company, however, said Medicine and Healthcare Products Regulatory Agency, UK, (UKMHRA) has eased the restrictions to an extent allowing it to supply most of the products manufactured at the said facility to the UK.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347